Primary Unknown Squamous Cell Carcinoma with the Anaplastic Lymphoma Kinase Fusion Gene That Was Effectively Treated with Alectinib: A Case Report
Open Access
- 8 July 2026
- journal article
- case report
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 904-910
Abstract
The anaplastic lymphoma kinase (ALK) fusion gene is expressed in 3%–5% patients with non-small cell lung cancer; targeting this gene with molecular targeted therapy results in a positive long-term prognosis. However, the ALK fusion gene expression rate is only 0.8% when restricted to pulmonary squamous cell carcinoma. A 61-year-old non-smoking woman had undergone partial resection of the right lower lobe for lung adenocarcinoma 5 years previously, and ALK fusion gene positivity was confirmed at that time. Computed tomography (CT) revealed subcarinal lymph node enlargement. Subsequent positron emission tomography-CT imaging showed high uptake at this site and in the hepatic hilar lymph nodes. Subcarinal and hilar lymph node biopsies resulted in a diagnosis of squamous cell carcinoma. Squamous cell carcinoma of unknown primary was diagnosed because only metastatic lymph nodes were identified without a detectable primary lesion. Furthermore, the clinical presentation was considered inconsistent with metastatic recurrence, given the distinct histopathological difference from the initial surgical specimen and long disease-free interval. Treatment with carboplatin and paclitaxel was initiated. Although initial tumor reduction was achieved, the lesion subsequently progressed. After next-generation sequencing revealed ALK fusion gene positivity, the introduction of alectinib was effective. Alectinib is effective against ALK fusion gene-positive squamous cell carcinoma of unknown primary.Keywords
This publication has 12 references indexed in Scilit:
- Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States - retrospective real world dataOncotarget, 2021
- Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case ReportCurrent Oncology, 2021
- Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinibLung Cancer, 2020
- Carcinoma of Unknown Primary withEML4-ALKFusion Response toALKInhibitorsThe Oncologist, 2019
- ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literatureBMC Cancer, 2017
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialThe Lancet, 2017
- Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer2015
- ALK-rearranged squamous cell lung cancer: a case report.2015
- Cancers of unknown primary origin: current perspectives and future therapeutic strategiesJournal of Translational Medicine, 2012
- Diagnostic and therapeutic management of cancer of an unknown primaryEuropean Journal of Cancer, 2003